Why are children on the NSW North Coast not being vaccinated against chickenpox?

Trent, Marianne

doi:10.1071/nb11014

Cited by 2 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prominence of electronic notification to the ACIR, either directly from patient management software or via the ACIR website, is consistent with the increase in electronic notifications nationally [ 27 ]. Although this method has its advantages, such as less delay and reduced staff time, there is a need to routinely verify transmission to avoid errors which would lead to under-reporting [ 41 ]. Given the reliance on electronic notification systems it is imperative that they are updated with vaccine-specific codes prior to the introduction of a new vaccine on the NIP.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the implementation of the 13-valent pneumococcal vaccine supplementary dose program in Australian primary health care settings

Ward

Trent

Hull

et al. 2015

BMC Health Serv Res

Self Cite

View full text Add to dashboard Cite

BackgroundThe availability of new pneumococcal conjugate vaccines covering a broader range of serotypes, has seen many countries introduce these into their national immunisation program. When transitioning from 7-valent to 13-valent pneumococcal conjugate vaccines, Australia is one of a small number of countries that included a supplementary dose of the 13-valent pneumococcal conjugate vaccine to offer protection against additional serotypes to an expanded age group of children. An evaluation of the implementation and uptake of the 13-valent pneumococcal conjugate vaccine supplementary dose was undertaken in two local health districts (LHDs) in New South Wales, Australia.MethodsA self-administered postal survey of immunisation providers in the Northern New South Wales and Mid North Coast LHDs. Trends in vaccine ordering were examined. Coverage was assessed using data from the Australian Childhood Immunisation Register (ACIR).ResultsOf the 177 surveys sent, 125 were returned (70%). Almost all providers (96%) were aware of the 13vPCV supplementary dose program though took an opportunistic approach to program promotion and parental reminders. Supplementary doses of 13vPCV were ordered for 37% of the eligible cohort, mostly in the program’s first six months. Coverage as recorded on the ACIR was 27%, though was lower in older children and those not due for scheduled childhood vaccines. Of the children who received the 13vPCV supplementary dose, 3% received it at the same time as vaccines due at 12-months of age, and 44% at the time of those due at 18-months of age.ConclusionDespite the high awareness of the program, reported coverage was lower than that for other PCV supplementary dose programs in Australia and internationally. This may be influenced by providers’ largely opportunistic approach to implementation, under-reporting to the ACIR or vaccine uptake. Lessons learned from this evaluation are relevant for future time-limited childhood vaccination programs. Prior to commencement, providers should be informed about the importance of catch-up/supplementary vaccination for their patients and their active role in promoting this. They should also receive program information before parents. An understanding of parental reasons for non-receipt of time-limited childhood vaccines and evaluation of the effect of aligning supplementary (or catch up) vaccination programs with the NIP schedule would be useful to inform future programs.

show abstract

Section: Discussionmentioning

confidence: 99%